Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In this study, researchers are comparing ado-trastuzumab emtansine with the usual treatment (docetaxel and trastuzumab) in people with recurrent, inoperable, or metastatic salivary gland cancer that makes the HER2 protein. Ado-trastuzumab emtansine is a monoclonal antibody (trastuzumab) linked to a chemotherapy drug (emtansine). Trastuzumab attaches to HER2 on cancer cells and delivers emtansine to kill them.
Researchers are comparing two different treatments for breast cancer that metastasized (spread) and makes high levels of the HER2 protein. The people in this study have metastatic HER2-positive breast cancer that keeps growing after trastuzumab deruxtecan (T-DXd). Or they may have had bad side effects from this drug and had to stop taking it.
The purpose of this study is to compare proton beam radiation therapy with intensity-modulated radiation therapy (IMRT) in patients with stage I-IVA esophageal cancer. Both approaches send radiation inside the body to a tumor without damaging much of the healthy tissue around it. However, proton beam radiation therapy uses protons while IMRT uses photons (high-energy x-rays).
Peritoneal mesothelioma is a cancer of the inner lining of the abdomen (belly). The people in this study will be having surgery to take out as much of the cancer as possible. They will also receive heated chemotherapy given directly into the abdomen to kill any remaining cancer cells.
After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.
Patients receiving certain drugs for breast cancer, such as doxorubicin or trastuzumab, may experience impaired heart function. Researchers at Memorial Sloan Kettering Cancer Center are conducting a study to see if it is possible to grow heart muscle cells ("cardiomyocytes") from blood or skin cells from breast cancer patients. The skin cells will be grown in a special mixture in the laboratory designed to transform them from skin cells into heart muscle cells.
Researchers want to see if ASTX727 is practical and safe for people with high-risk clonal cytopenia of undetermined significance (CCUS). With CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells. CCUS can lead to precancerous conditions such as myelodysplastic syndrome or blood cancers such as acute myeloid leukemia.
Researchers want to see if bulumtatug fuvedotin works well against breast cancer. The people in this study have triple-negative breast cancer (TNBC) that came back or spread after treatment. 
The purpose of this study is to assess the feasibility of a new approach to treat people with T4 breast cancer who have already received chemotherapy. T4 breast cancer occurs when the cancer has grown beyond normal breast tissue and into the chest wall or skin or has become swollen and causes pain. Doctors normally treat T4 breast cancer with chemotherapy followed by mastectomy and removal of underarm (axillary) lymph nodes. After mastectomy, patients normally receive radiation therapy and then have breast reconstruction surgery many months to years after completing radiotherapy.
